Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo
NCT07283562Completed
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Jan 2023
- Primary completion
- Oct 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gastrodin in sensorineural hearing loss (SNHL) and vertigo (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Pure Tone Average at Week 4 and Dizziness Handicap Inventory at Week 4. Started Jan 2023; status: completed.
02
Drugs
gastrodin
03
Conditions
sensorineural hearing loss (SNHL)vertigo
Beyond the preview
Go deeper on NCT07283562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283562.